Barron Associates

Open enrollment across a mixed-phase pipeline

According to ClinicalTrials.gov-derived indexes, Barron Associates sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).

10 total trials 1 currently recruiting 6 completed top decile by trial count

Barron Associates: 10 sponsored US clinical trials, 1 recruiting.

Barron Associates sponsors 10 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 6 completed. The most-studied condition in this pipeline is Ocular Motility Disorders, with 1 trials.

Top-decile sponsor footprint

Barron Associates ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

What is open in the Barron Associates pipeline

1 recruiting of 10 indexed (10% open); 6 completed (60%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Ocular Motility Disorders (1 trial), 6 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Barron Associates: open-pipeline peers nationwide

Peers matched on 10 registered trials and 10% open enrollment, not the therapeutic-area sidebar.

Barron Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 510152025 0%10%20%30%40% Total trials Recruiting share Barron AssociatesAdamas PharmaceuticalsAdverum BiotechnologiesAevi Genomic Medicine, LLC, a Cerecor companyAgouron PharmaceuticalsAbiomedAimmune TherapeuticsAltria Client ServicesAlzheimer's Disease Cooperative Study (ADCS)
Barron Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Barron Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 10 trials (± recruiting share)

Sponsors near 10% open enrollment (± trial volume)

What to do with this Barron Associates page

10 registered trials is a research-attention snapshot, not an endorsement of Barron Associates or any single study.

  • 1 of Barron Associates's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Ocular Motility Disorders is the condition Barron Associates studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Ocular Motility Disorders trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Barron Associates pipeline card: 10 registered trials from official public datasets.Report a data error.